Title: Haloperidol vs. ondansetron for cannabis hyperemesis syndrome<br/>Author: Hong Kim<br/><a href='http://umem.org/profiles/faculty/526/'>[Click to email author]</a><hr/><p>
</p>
<p>
Patients with cannabis hyperemesis syndrome experience recurrent/protracted nausea/vomiting. Cases of cannabis hyperemesis syndrome may increase as cannabis use becomes more common in the United States.</p>
<p>
A randomized control trial (triple-blind) was conducted to compare haloperidol (0.05 or 0.1 mg/kg) IV or ondansetron 8 mg IV. Primary outcome was reduction of abdominal pain and nausea from baseline (on a 10 cm visual analog scale) 2 hours after treatment.</p>
<p>
Results</p>
<ul>
<li>
33 subjected were randomized to haloperidol (n=13) and ondansetron (n=17)</li>
<li>
30 used 1.5 gm/day since 19 years of age.</li>
<li>
Haloperidol was superior to ondansetron
<ul>
<li>
2.3 cm difference in pain and nausea</li>
<li>
Less use of rescue antiemetics (31% vs. 59%)</li>
<li>
Shorter time to ED departure (3.1 hours vs. 5.6 hours)</li>
</ul>
</li>
</ul>
<p>
Conclusion</p>
<ul>
<li>
In this small trial, haloperidol (0.05 or 0.1 mg/kg IV) was superior to ondansetron (8 mg IV) in the treatment of acute cannabis associated hyperemesis </li>
</ul>
<fieldset><legend>References</legend>
<p>
Ruberto AJ. et al. Intravenous haloperidol versus ondansetron for cannabis hyperemesis syndrome (HaVOC): a randomized controlled trial. Annals of Emergency Medicine. Nov 2020</p>
<p>
<span style="color: rgb(35, 151, 210); font-family: AdvTT7169e447; font-size: 8pt; caret-color: rgb(0, 0, 0);">https://doi.org/10.1016/j.annemergmed.2020.08.021</span></p>
</fieldset>